Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01743807
Recruitment Status : Terminated (SBI Biotech who provided the drug for this study has decided to no longer support the study or GNKG168.)
First Posted : December 6, 2012
Last Update Posted : November 24, 2015
Information provided by (Responsible Party):
Nobuko Hijiya, MD, Therapeutic Advances in Childhood Leukemia Consortium

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : July 2014
  Actual Study Completion Date : July 2014